Dynasil Corporation of America announced the results of operations for the first quarter of Fiscal Year 2010 ending December 31, 2009. Revenues for the quarter ended December 31, 2009 increased by 13.3% to $9.9 million compared to revenues of $8.8 million for the quarter ended December 31, 2008. Income from Operations for the quarter increased by 63% to $1,071,836 compared to $657,370 for the quarter ended December 31 2008. Net income for the quarter was $613,769 or $0.04 per share, an increase of 73% compared to $355,639 or $0.02 per share, for the quarter ended December 31, 2008. These gains in profitability were spurred primarily by an increased demand for products and services, which generated a 13.3% revenue increase, as well as improved profitability in the Products and Instruments businesses. Income before Income Taxes was $909,395 against $470,573 for the same period a year ago.

Dynasil Corporation of America announced earnings results for the year ended September 30, 2009. Income from Operations was $2,843,077 as compared to $1,449,814 for the same period prior year. Income before income taxes was $2,107,760 as compared to $1,235,724 for the same period prior year. Diluted income per share was $0.08 as compared to $0.12 for the same period prior year. Revenues doubled from $17.1 million to $34.4 million. Net income increased by 33.5% from $1.16 to $1.55 million. Net operating loss carry-forwards for federal taxes were exhausted during fiscal year 2008, so fiscal year 2009 net income was affected by provisions for increased federal taxes, as well as higher interest costs relating to the RMD acquisition.

Dynasil Corporation of America announced that Dr. Michael Joyner of the Mayo Clinic and David Kronfeld of JK&B Capital of Chicago have been nominated for election to the Dynasil Board of Directors at its February 3, 2010 Annual Meeting. Michael J. Joyner, M.D. serves as the Associate Dean for research at Mayo Clinic in Rochester, Minnesota where he also is Deputy Director for Research, associate program director of the Center of Translational Science Activities and a consultant to the Department of Anesthesiology.

Dynasil Receives Additional Homeland Security Funding for Nuclear Detection Materials

Dynasil Receives Additional Homeland Security Funding for Nuclear Detection Materials

Dynasil Announces Fiscal Year 2009 Results with a Doubling of Revenues and Income from Operations

Dynasil Announces the Nominations of Dr. Michael Joyner of the Mayo Clinic and Mr. David Kronfeld of JK & B Capital as New Directors

Dynasil Announces First Quarter 2010 Results

Dynasil Announces First Quarter 2010 Results

Dynasil Announces Fiscal Year 2009 Results with a Doubling of Revenues and Income from Operations

DYNASIL CORP OF AMERICA Files SEC form 10-K, Annual Report

DYNASIL CORP OF AMERICA Files SEC form 8-K, Other Events

Dynasil Announces the Nominations of Dr. Michael Joyner of the Mayo Clinic and Mr. David Kronfeld of JK & B Capital as New Directors

DYNASIL CORP OF AMERICA Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal

DYNASIL CORP OF AMERICA Files SEC form 8-K, Change in Directors or Principal Officers

DYNASIL CORP OF AMERICA Files SEC form 8-K, Change in Directors or Principal Officers

DYNASIL CORP OF AMERICA Files SEC form 10-Q, Quarterly Report

Dynasil Ranked Number 207 Fastest Growing Company in North America on Deloitte's 2009 Technology Fast 500

DYNASIL CORP OF AMERICA Files SEC form 8-K, Other Events

Dynasil Announces Mr. Peter Sulick Elected Chairman of the Board of Directors

Dynasil Announces Mr. Ken Morse as Commercialization Advisor

NJBIZ Honors New Jersey's Top Fifty Fastest Growing Companies - Dynasil Corporation of America Announces 29th Place Ranking

Dynasil Corporation Retains Carpe DM, Inc. for Investor Relations